Features

Realizing the growth potential of the biological material industry as the core of the pharmaceutical industry, Boryung started a new outfit, Boryung Biopharma, in 1991 to churn out innovative biotech material.


After the successful launching of the Influenza HA Vaccine, the company boasts many other sophisticated products such as
ZEROTYPH, capsule-type vaccines for typhoid fever, the world's second development, and Heptis-B, a 2nd generation hepatitis-B vaccine
using gene recombination technology. Today, the company applies the most advanced biotechnology to invent new preventive medicines.


We at Boryung Biopharma plan to leverage our gene combination technology in developing life-saving vaccines, diagnosis kits, and cure for breast cancer
so that we can win stiff competition in the 21st century. We believe that our products will benefit people around the world and lift the biotech industry to a higher level.